SCHEMBL4025974

SCHEMBL4025974

CCCCn1nc(-c2ccc(O)c(O)c2)c2cc(Cl)c(F)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.47
PIK3CA P42336 3/20 0.34
MTOR P42345 3/20 0.34
ICMT O60725 2/20 0.34
PIK3CD O00329 2/20 0.34
ABL1 P00519 2/20 0.34
EGFR P00533 2/20 0.34
HCK P08631 2/20 0.34
SRC P12931 2/20 0.34
KDR P35968 2/20 0.34
PIK3CB P42338 2/20 0.34
PIK3CG P48736 2/20 0.34
EPHB4 P54760 2/20 0.34
PRKDC P78527 2/20 0.34
RICTOR Q6R327 1/20 0.33
RPTOR Q8N122 1/20 0.33
MAPKAP1 Q9BPZ7 1/20 0.33
MLST8 Q9BVC4 1/20 0.33
RORC P51449 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030925 0.89 ESR1 (0.60) ESR1TP53
SCHEMBL4033245 0.87 ESR1 (0.44) ESR1PIK3CAMTORPIK3CDABL1
SCHEMBL4032548 0.83 ESR1 (0.55) ESR1TP53
SCHEMBL4032378 0.83 ESR1 (0.44) ESR1PIK3CAMTORPIK3CDABL1
SCHEMBL4029614 0.82 ESR1 (0.39) ESR1PIK3CAMTORPIK3CDABL1
SCHEMBL4028787 0.81 ESR1 (0.47) ESR1SRCRORCTP53
SCHEMBL4029629 0.78 ESR1 (0.52) ESR1RORC
SCHEMBL4035483 0.78 ESR1 (0.44) ESR1RORCPGR
SCHEMBL4036253 0.77 ESR1 (0.77) ESR1RORCTP53
SCHEMBL4035727 0.77 ESR1 (0.57) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885PIK3CA 2617/4885MTOR 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.